Cardiovascular Effects of Gonadotropin-releasing Hormone (GnRH) Antagonists Compared With Agonists in Prostate Cancer: A Systematic Review
Pooled resultResult — go to the resultOdds ratio 0.57 95% CrI 0.37–0.86Authors' conclusion
Notwithstanding these limitations, the available data suggest that GnRH antagonists are associated with fewer cardiovascular events, and possibly mortality, compared with GnRH agonists.
Study context
- Population
- Patients with advanced prostate cancer receiving androgen deprivation therapy
- Participants
- 4,248 patients · 11 RCTs
- Comparison
- GnRH antagonists vs GnRH agonists
- GnRH antagonistsn = 2,655
- GnRH agonistsn = 1,593reference
- Outcome
- MACE:
- MI
- CNS haemorrhages and cerebrovascular conditions
- All-cause mortality
- MedDRA terms
Methodological detailsrandom effects, open-label trials, Max trial duration 3 to 36 months (median = 12 months), Only 1 trial used blinded, adjudicated events; potential bias in all trials (open-label)
- Random effects
- Open-label trials
- Max trial duration 3 to 36 months (median = 12 months)
- Only 1 trial used blinded, adjudicated events; potential bias in all trials (open-label)
Pooled result
As reported in the abstract
Odds ratio
0.57
95% CrI 0.37–0.86
Events by group
GnRH antagonists vs GnRH agonists
OR 0.57 (95% CrI 0.37–0.86)
Further pooled results
| Outcome | OR (95% CrI) | |
|---|---|---|
| All-cause death · CrI | 0.58 (0.32–1.08) | |
| 0.20.5125Odds ratio (log scale) |
- All-cause death: 95% CrI
Original publication
Cardiovascular Effects of GnRH Antagonists Compared With Agonists in Prostate Cancer: A Systematic Review. JACC CardioOncol. Published 1 August 2023. doi:10.
Summarised from the published abstract; every number is checked against it